At the presentation of the Pharvaris financial results for the first quarter ended 31 March 2021, co-founder and CEO Berndt Modig said:
“We continue to execute on a development strategy which we believe provides value to shareholders and patients, as demonstrated by the continued enrollment of our Phase 2 on-demand study of PHVS416, from which we plan to report data next year. In order to meet the unmet need of many HAE patients demanding oral alternative therapies, we plan to initiate our HAE CHAPTER-1 Phase 2 prophylactic study of PHVS416 this year. Pharvaris remains committed to providing access to medicines for patients in need.”
From the pipeline:
PHVS719 is an extended-release formulation of PHA121 intended for use in the prophylactic treatment of HAE. The company expects to initiate a Phase 1 pharmacokinetics study by the end of 2021.